Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pemetrexed Dipotassium in Malignant Pleural Mesothelioma: NCT03760575 Clinical Landscape Report 2026
16 October 2026
NCT03760575 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Malignant Pleural Mesothelioma: NCT03762018 Clinical Landscape Report 2026
16 October 2026
NCT03762018 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT03770403 Clinical Landscape Report 2026
16 October 2026
NCT03770403 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Spironolactone in Muscular Dystrophy, Duchenne: NCT03777319 Clinical Landscape Report 2026
16 October 2026
NCT03777319 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Unresectable Pleural Malignant Mesothelioma: NCT03786419 Clinical Landscape Report 2026
16 October 2026
NCT03786419 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Bisoprolol Fumarate in Cardiomyopathy, Dilated: NCT03779646 Clinical Landscape Report 2026
16 October 2026
NCT03779646 clinical landscape for Cardiomyopathy, Dilated: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Paclitaxel in Primary peritoneal carcinoma: NCT03834948 Clinical Landscape Report 2026
16 October 2026
NCT03834948 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ataluren in Muscular Dystrophy, Duchenne: NCT03796637 Clinical Landscape Report 2026
16 October 2026
NCT03796637 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BLS-ILB-MD1 in Muscular Dystrophy, Duchenne: NCT03789734 Clinical Landscape Report 2026
16 October 2026
NCT03789734 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant coagulation factor VIII ( Sino Cell Technologies) in Hemophilia A: NCT03815318 Clinical Landscape Report 2026
16 October 2026
NCT03815318 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BBT-877 in Idiopathic Pulmonary Fibrosis: NCT03830125 Clinical Landscape Report 2026
16 October 2026
NCT03830125 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pleightlet in Hemophilia A: NCT03818763 Clinical Landscape Report 2026
16 October 2026
NCT03818763 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.